Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target...

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment but faces challenges in T-cell lymphomas (TCL) due to antigen identification difficulties.
• CD37 has been identified as selectively expressed on malignant T cells in a subset of TCL patients.

Purpose of the Study:

• To develop and evaluate CAR T cells targeting CD37 for TCL treatment.
• To investigate the combination of CAR-37 T cells with BH3 mimetics to enhance therapeutic efficacy and minimize toxicity.

Main Methods:

• Development of CAR-37 T cells targeting CD37-positive TCL.
• Assessment of CAR-37 T cell activity, including apoptosis induction.
• Identification of targetable BH3 dependencies in TCL models.
• Combination therapy studies using CAR-37 T cells and BH3 mimetics (e.g., AZD5991 for MCL-1).
• Evaluation of combination therapy effects on TCL cell killing, CAR-T cell function, and in vivo efficacy in xenografted mice.

Main Results:

• CAR-37 T cells specifically target CD37-positive TCL and activate the intrinsic apoptotic pathway.
• BH3 mimetics did not impair CD37 binding or CAR-37 T cell function.
• Combination of CAR-37 T cells with the MCL-1 inhibitor AZD5991 significantly enhanced anti-TCL response and prolonged survival in xenograft models.
• TCL models showed dependence on specific BH3 proteins, suggesting personalized therapeutic strategies.

Conclusions:

• CAR-37 T cell therapy is a viable strategy for CD37-positive TCL.
• Combining CAR-37 T cells with personalized BH3 mimetic therapy can improve therapeutic index and efficacy.
• This combination approach holds potential for treating TCL and potentially other hematological malignancies.